Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the Anticipated CAGR of the Chronic Pruritus Therapeutics Market, and What Factors Will Drive It?
Over the past few years, the market size for chronic pruritus therapeutics has seen robust growth. It is projected to escalate from $10.17 billion in 2024 to $10.94 billion in 2025, sustaining a compound annual growth rate (CAGR) of 7.6%. This previous period’s growth can be credited to an increasing incidence of chronic pruritus, a rising need for successful treatments, growing regulatory acceptance, a surge in product approvals, and a rise in mergers, collaborations, and acquisitions among industry players.
The market size for chronic pruritus therapeutics is anticipated to witness considerable expansion in the coming years. The projected growth indicates a likelihood of reaching $14.49 billion by 2029, boasting a compound annual growth rate (CAGR) of 7.3%. The expected growth during this forecast period is linked to increased awareness, a surge in atopic dermatitis, a heightened emphasis on personalized medicine, a rising occurrence of skin disorders, and an expanding patient pool. Notable trends predicted for this forecast period encompass the introduction of unique medicines, the production of ground-breaking biologics and targeted therapies, advancements in technology, the incorporation of improved drug delivery systems, as well as collaborative efforts between pharmaceutical companies and research institutions, and the growth of digital health technologies such as telemedicine.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Pruritus Therapeutics Market?
The chronic pruritus therapeutics market’s growth is expected to surge forward due to the increasing occurrence of atopic dermatitis. Atopic dermatitis, or AD, is renowned for its chronic inflammation of the skin, with symptoms such as redness, dryness, itching, and irritation, typically affecting those with a family history of allergies, asthma, or hay fever. The heightened presence of atopic dermatitis is linked to a mix of factors such as genetic predisposition, alterations to the environment, lifestyle changes, the hygiene hypothesis, increased exposure to allergens, and imbalances in the skin’s microbiome. Therapies for chronic pruritus provide relief from the relentless itching affiliated with atopic dermatitis by focusing on the inflammatory pathways beneath the surface, limiting skin irritation, and enhancing patient comfort. For example, the International Eczema Council, a nonprofit organization based in the US, reported that in 2022, around 223 million people worldwide (GBD 2022), including 43 million children aged between 1-4, suffered from atopic dermatitis. This underscores the condition’s tremendous early childhood prevalence. Hence, the burgeoning presence of atopic dermatitis is propelling the chronic pruritus therapeutics market’s growth.
Which Key Market Segments Comprise the Chronic Pruritus Therapeutics Market and Drive Its Revenue Growth?
The chronic pruritus therapeutics market covered in this report is segmented –
1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types
2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types
3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers
Subsegments:
1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics
4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants
5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy
7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp
Which Areas Are Leading Regions in the Chronic Pruritus Therapeutics Market Expansion Across the Globe?
North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theChronic Pruritus Therapeutics Market Over the Coming Years?
Leading enterprises within the sector of chronic pruritus therapeutics are concentrating on creating novel formulations, including intravenous (IV) injections, in a bid to boost treatment effectiveness and expedite patient relief. The use of IV injections is beneficial in pruritus treatment as they deliver drugs like antihistamines or corticosteroids instantly into the bloodstream to relieve itching and diminish inflammation. As an exemplification, Cara Therapeutics Inc., a firm situated in the US that produces therapeutics, revealed in September 2023 that its collaborator, Maruishi Pharmaceutical Co. Ltd., a Japanese pharmaceutical firm, obtained the endorsement for the Korsuva IV injection syringe from Japan’s Ministry of Health, Labour and Welfare. This pruritus treatment for hemodialysis patients was given approval based on favorable outcomes from a Phase 3 clinical trial by Maruishi in alliance with Kissei Pharmaceutical Co. Ltd. The treatment demonstrated considerable enhancements in itching scores in comparison to a placebo, and was well-received by patients. The validation also activated a $1.5 million milestone remittance to Korsuva’s creator, Cara Therapeutics, under the stipulations of its licensing contract with Maruishi.
View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report
How Is the Chronic Pruritus Therapeutics Market Conceptually Defined?
Chronic pruritus therapy refers to treatments aimed at managing or alleviating persistent itching (pruritus) that lasts for six weeks or more. Chronic pruritus is managed with a combination of therapies that are tailored to the specific underlying cause, and treatment can be adjusted based on how the patient responds.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model